What does Akebia Therapeutics, Inc. do?
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease…
What is Akebia Therapeutics, Inc.'s P/E and P/B ratio?
Akebia Therapeutics, Inc. has a P/E ratio of -4.7 and a P/B ratio of 6.23.
What is Akebia Therapeutics, Inc.'s debt-to-equity ratio?
Akebia Therapeutics, Inc. has a debt-to-equity ratio of 7.96.
How much does Akebia Therapeutics, Inc. owe compared with what it owns?
Akebia Therapeutics, Inc. owes $0.93 for every $1 it owns (balance sheet Jun 2026), which is high.
What is Akebia Therapeutics, Inc.'s Positivity rank?
Akebia Therapeutics, Inc. is ranked #6,015 of 6,774 companies globally and #3,392 of 4,000 in United States on PositoAI, with a Positivity Score of 12,121.
Does Akebia Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Akebia Therapeutics, Inc..
Where can I read the latest news about Akebia Therapeutics, Inc.?
Recent headlines about Akebia Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Akebia Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Akebia Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.